Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia

American Journal of Clinical Nutrition

Volumn 80, Issue 1, 2004, Pages 114-122

  Quadri, Pierluigi ^a   Fragiacomo, Claudia ^a   Pezzati, Rita ^a   Zanda, Enrica ^a   Forloni, Gianluigi ^b   Tettamanti, Mauro ^b   Lucca, Ugo ^b  

^a Ospedale Beata Vergine   (Switzerland)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alzheimer disease; Folate; Homocysteine; Mild cognitive impairment; Vascular dementia; Vitamin B 12

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; HUMAN; HYPERHOMOCYSTEINEMIA; LEUKOARAIOSIS; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RATING SCALE; SCORING SYSTEM; TEMPORAL LOBE; VITAMIN BLOOD LEVEL; AGED; ANALYSIS OF VARIANCE; BLOOD; CROSS-SECTIONAL STUDY; FEMALE; MALE; RISK; RISK FACTOR; SWITZERLAND;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DEMENTIA, VASCULAR; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; ODDS RATIO; RISK FACTORS; SWITZERLAND; VITAMIN B 12;

EID: 3042784367     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-4.
2. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277:813-7.
3. Moroney JT, Bagiella E, Desmond DW, et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology 1997;49:1096-105.
4. Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999;174:45-50.
5. Zekry D, Duyckaerts C, Belmin J, Geoffre C, Moulias R, Hauw J-J. Alzheimer's disease and brain infarcts in the elderly. Agreement with neuropathology. J Neurol 2002;249:1529-34.
6. Breteler MMB. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000;21:153-60.
7. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
8. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274: 1049-57.
9. Wald DS, Law M, Morris J K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-6.
10. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 2002;288: 2015-22.
11. Dudman NPB. An alternative view of homocysteine. Lancet 1999;354: 2072-4.
12. Brattström L, Wilcken DEL. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000;72:315-23.
13. Ueland PM, Refsum H, Beresford SAA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72: 324-32.
14. Scott JM. Homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72:333-4.
15. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease. Causal or casual? Arch Intern Med 2000;160:422-34.
16. Nilsson K, Gustafson L, Fäldt R, et al. Hyperhomocysteinaemia - a common finding in a psychogeriatric population. Eur J Clin Invest 1996; 26:853-9.
17. Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol 1997;52A:M76-9.
18. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B-12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-55.
19. McCaddon A, Davies G, Hudson PO, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235-9.
20. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord 1999;10:12-20.
21. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002;33:2351-6.
22. Fekkes D, van der Cammen TJM, van Loon CPM, et al. Abnormal amino acid metabolism in patients with early stage Alzheimer dementia. J Neural Transm 1998;105:287-94.
23. Dresner Pollak R, Pollak A, Idelson M, Bejarano-Achache I, Doron D, Blumenfeld A. The C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and vascular dementia. J Am Geriatr Soc 2000;48:664-8.
24. Ravaglia G, Forti P, Maioli F, et al. Elevated plasma homocysteine levels in centenarians are not associated with cognitive impairment. Mech Aging Dev 2000;121:251-61.
25. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B-6, and vascular disease in AD patients. Neurology 2002;58: 1471-5.
26. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MMB. Total homocysteine and cognitive decline in a community-based sample of elderly subjects. The Rotterdam Study. Am J Epidemiol 1999; 150:283-9.
27. Seshadri S, Beiser A, Selhub J, et al. Plasmahomocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-83.
28. Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary I. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002;75:908-13.
29. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-37.
30. Weir DG, Molloy AM. Microvascular disease and dementia in the elderly: are they related to hyperhomocysteinemia? Am J Clin Nutr 2000; 71:859-60.
31. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-13.
32. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Sen-ices Task Force on Alzheimer's Disease. Neurology 1984; 34:939-44.
34. Morris JC. Clinical assessment of Alzheimer's disease. Neurology 1997; 49(suppl 3):S7-10.
35. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke 1983;14:399-401.
36. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-72.
37. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-4.
38. Jobst KA, Smith AD, Szatmari M, et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 1992;340:1179-83.
39. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
40. Basun H, Fratiglioni L, Winbland B. Cobalamin levels are not reduced in Alzheimer's disease: results from a population-based study. J Am Geriatr Soc 1994;42:132-6.
41. Crystal HA, Ortof E, Frishman WH, Gruber A, Hershman D, Aronson M. Serum vitamin B-12 levels and incidence of dementia in a healthy elderly population: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc 1994;42:933-6.
42. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.
43. Thirup P, Ekelund S. Day-to-day, postprandial, and orthostatic variation of total plasma homocysteine. Clin Chem 1999;45:1280-3.
44. Clarke R, Lewington S, Donald A, et al. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk 2001;8:363-9.
45. Clarke R, Joachim C, Esiri M, et al. Leukoaraiosis at presentation and disease progression during follow-up in histologically confirmed cases of dementia. Ann N Y Acad Sci 2000;903:497-500.
46. Hogervorst E, Mendes Ribeiro H, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neural 2002;59:787-93.
47. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 2002;51:285-9.
48. Sachdev PS, Valenzuela M, Wang XL, Looi JCL, Brodaty H. Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 2002;58:1539-41.
49. Dufouil C, Alpérovitch A, Ducros V, Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol 2003;53:214-21.
50. Matsui T, Arai H, Yuzuriha T, et al. Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke 2001; 32:1116-9.
51. Vermeer SE, den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003;34:392-6.
52. Riggs KM, Spiro A III, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996;63:306-14.
53. Lipton SA, Kim W-K, Choi Y-B, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 1997;94:5923-8.
54. Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920-6.
55. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency, and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 2002;22:1752-62.
56. Williams JH, Pereira EAC, Budge MM, Bradley KM. Minimal hippocampal width relates to plasma homocysteine in community-dwelling older people. Age Ageing 2002;31:440-4.
57. den Heijer T, Vermeer SE, Clarke R, et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 2003;126:170-5.
58. Snowdon DA, Tully CL, Smith CD, Perez Riley K, Markesbery WR. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun Study. Am J Clin Nutr 2000;71:993-8.
59. Duan W, Ladenheim B, Cutler RG, Kruman H, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002;80:101-10.
60. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998;316:894-8.
61. Aisen PS, Egelko S, Andrews H, et al. A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry 2003;11:246-9.